Story perspectives

FDA Issues Guidance for Safer CAR-NK Therapies

10/3/2025

24 5

Summary

Story summary

The FDA issued guidance on allogeneic chimeric antigen receptor–natural killer (CAR-NK) therapies, emphasizing manufacturing controls.
Key areas include potency, donor cell characterization, and genome-editing safety for iPSC-derived products.
The FDA cites over 200 complete response letters (CRLs), stressing alignment of product quality testing with expectations.
Developers should adopt a matrixed control strategy integrating multiple analytical methods for consistency and safety.

1 of 1

Story summary

The FDA issued guidance on allogeneic chimeric antigen receptor–natural killer (CAR-NK) therapies, emphasizing manufacturing controls.
Key areas include potency, donor cell characterization, and genome-editing safety for iPSC-derived products.
The FDA cites over 200 complete response letters (CRLs), stressing alignment of product quality testing with expectations.
Developers should adopt a matrixed control strategy integrating multiple analytical methods for consistency and safety.